Continuum of Care in Hospitalized Patients With Opioid or Stimulant Use Disorder and Infectious Complications of Drug Use - Substance Use/ID Integrated Clinic vs. TAU to Prevent Infection Related Readmission
Elana Rosenthal
Summary
This is a two-group randomized controlled trial conducted at five hospitals across the U.S. designed to test the effectiveness of an Integrated infectious diseases/Substance Use Disorder outpatient clinic (IC) compared to treatment as usual aimed at reducing infection related readmissions and improving health outcomes in people hospitalized with an infection related to injecting opioids or stimulants.
Description
This is a phase III two arm randomized controlled trial to determine the impact and Integrated infectious diseases (ID) and Substance Use Disorder outpatient clinic (IC) compared to treatment as usual on infection related rehospitalization in individuals hospitalized with infections due to injecting opioids or Stimulants, in the 6 month time period after discharge. This study includes both cost effectiveness and implementation outcomes. (1) IC will provide facilitated linkage to a clinic providing medical treatment aimed at treating substance use disorder (SUD), resolving the index infection,…
Eligibility
- Age range
- 18+ years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: 1. Age ≥ 18 years 2. Admitted to study hospital (defined as hospitalized with a primary team that is not Emergency Medicine) 3. Injection opioid or stimulant use in past 90 days - per patient self-report 4. Active suspected or confirmed qualifying infection (see list) at time of admission. Qualifying infections: * Non-vertebral osteomyelitis * Vertebral osteomyelitis or discitis * Epidural, subdural, or extradural abscess * Intracranial or intraspinal abscess * Native joint septic arthritis * Prosthetic joint septic arthritis * Blood stream infection (bacterial or fungal…
Interventions
- BehavioralIntegrated Infectious Diseases and Substance Use Disorder Clinic (IC)
Integrated medication for opioid/stimulant use disorder and infectious disease care provided into single appointment either in person or via telemedicine with a minimum of monthly appointments for 6 months.
Locations (4)
- George Washington UniversityWashington D.C., District of Columbia
- Emory UniversityAtlanta, Georgia
- University of Maryland BaltimoreBaltimore, Maryland
- West Virginia UniversityMorgantown, West Virginia